A push for transparency: US to make all federally-funded research public

Paul Schloesser

Associate Editor

A few months after a leadership shakeup, the White House’s Office of Science and Technology Policy (OSTP) is launching one of its most ambitious policy changes to date by making all taxpayer-funded research more accessible to the public.

In the eight-page memo released Thursday, OSTP director Alondra Nelson, who replaced ousted director Eric Lander earlier this year, called on agencies to make publications and research paid for with taxpayer dollars publicly accessible, for free, without any restriction.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

TRENDING NOW

A push for transparency: US to make all federally-funded research public

Paul Schloesser

Associate Editor

To read Endpoints News become a free subscriber

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

FDA commissioner says drug prices are too high, calls for better evidence generation

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

A push for trans­paren­cy: US to make all fed­er­al­ly-fund­ed re­search pub­lic

Paul Schloesser

Associate Editor

To read Endpoints News become a free subscriber

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

Af­ter gene ther­a­py deaths, Astel­las to re­vis­it fa­tal neu­ro­mus­cu­lar con­di­tion in part­ner­ship with biotech start­up

Up­stream Bio match­es first fund­ing round with an­oth­er $200M to get asth­ma drug to PhI­II

FDA com­mis­sion­er says drug prices are too high, calls for bet­ter ev­i­dence gen­er­a­tion

4DMT's in­hal­able gene ther­a­py for cys­tic fi­bro­sis shows ear­ly pos­i­tive signs in tiny group of pa­tients

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

A push for transparency: US to make all federally-funded research public

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

FDA commissioner says drug prices are too high, calls for better evidence generation

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape